ABSTRACT The 0.5% ivermectin topical cream formulation was not directly ovicidal to treated eggs of head lice, as hatchability was not decreased. Nevertheless, the percent of hatched lice from treated eggs that took a blood meal signiÞcantly decreased (80 Ð95%) compared with lice that hatched from untreated eggs and all treated lice died within 48 h of hatching, including those that fed. Dilutions of ivermectin formulation of 0.15 and 0.2 g/ml, which were topically applied to 0 Ð 8 d old eggs, were not lethal to lice at 24 h posteclosion. However, 9 and 16% less lice fed when hatched from these treated eggs, respectively. Total [ 3 H] inulin ingested by untreated Þrst instars signiÞcantly increased over a 48 h feeding interval but was signiÞcantly less in instars that hatched from eggs receiving the 0.15 (36% less) and 0.2 (55% less) g/ml ivermectin treatments compared with placebo. The reduced feeding that occurred after the 0.15 and 0.2 g/ml ivermectin treatments occurred in the absence of mortality and suggests a unique mode of action of ivermectin on feeding that is separate from the mode of action of ivermectin leading to mortality. Failure of hatched instars to take a blood meal after egg treatments with formulated ivermectin is likely responsible for its action as a posteclosion nymphicide.
Insecticide resistance to currently used pediculicides, including permethrin, synergized pyrethrins and malathion, has occurred worldwide in human head louse populations (Lee et al. 2000; Yoon et al. 2003 Yoon et al. , 2004 Yoon et al. , 2006 . A crisis, therefore, exists in the chemical control of head lice and makes the search for new pediculicide products with novel modes of action a critical need.
Ivermectin is a macrocyclic lactone produced fermentatively by Streptomyces avermitilis and is a widely used oral anthelmintic agent for both humans and companion animals (Stevens and Breckenridge 2001) . It has a unique mode of action by reducing motility and feeding in treated nematodes (Fisher and Mrozik 1984 , Kotze 1998 , Sheriff et al. 2005 . In addition to muscles used in motility, ivermectin also acts to paralyze the muscles associated with the pharyngeal pump, inhibiting the pumping action needed for feeding and attachment (Brownlee et al. 1997 ). The concentration of ivermectin needed to cause paralysis of the pharyngeal pump is 10-to 100-fold lower than the concentration needed to cause mortality (Gill et al. 1995 , Martin 1996 .
Ivermectin has been shown to increase chloride permeability in insect (Duce and Scott 1985, Kane et al. 2000) and nematode (Dent et al. 1997 , Hejmadi et al. 2000 neurons and muscle membranes through binding to glutamate-gated chloride ion channels. These channels are highly expressed in the neuromuscular system of the pharyngeal pump in the mouthparts of the free living nematode, Caenorhabditis elegans, which has been shown to be highly sensitive to ivermectin. It is believed that during de-worming with ivermectin, nematode parasites are killed by ivermectin acting on glutamate-gated chloride channels in the cells of the neuromuscular system. Ivermectin increases Cl Ϫ inßux, which hyperpolarizes the cells, leading to paralysis of the mouthparts. This action causes the worms to detach from the mammalian gut and be excreted (Pemberton et al. 2001, Wolstenholme and Rogers 2005) . A similar mode of action in head lice, however, has not been directly characterized.
Additional sites of action for ivermectin include GABA-gated chloride channels in vertebrate and invertebrate nervous systems (Bloomquist 2003) and histamine-gated chloride channels (HisCl) in insects and nematodes (McCavera et al. 2007) .
Recently, successive oral ivermectin treatments have been used to treat hard-to-control head louse infestations (Chosidow et al. 2010 , Currie et al. 2010 . Ivermectin also has been formulated as a less invasive topically applied pediculicide that possesses the abil-ity to kill permethrin-resistant head lice (Strycharz et al. 2008) . The need for successive treatments in the oral ivermectin studies indicates that one treatment, while effective against feeding lice in situ, needs to be supplemented by a second systemic treatment to kill hatchlings that emerge from eggs present at the time of the initial treatment. This implies an absence of an ovicidal effect of oral ivermectin, but such activity of the topically applied ivermectin formulation has not yet been investigated in head lice. Therefore, the purpose of this current study is to determine the ovicidal activity of formulated ivermectin topically applied to head louse eggs, and to assess the ability of lice that hatched from treated eggs to feed. If lice that hatch from treated eggs fail to feed, it is possible that this action may be mediated by glutamate-gated chloride channels expressed in the neuromuscular aspect of their piercing-sucking mouthparts.
Materials and Methods
Human Head Lice. The SF-HL strain of permethrin-resistant human head lice (Pediculus humanus capitis De Geer, Anoplura: Pediculidae) was collected from infested children in Plantation and Homestead, FL, and maintained on an in vitro rearing system at the University of Massachusetts at Amherst, MA, as described by Yoon et al. (2006) . Lice have been maintained without a human host on the in vitro rearing system for 24 Ð36 generations. Permethrin-resistant SF-HL have been selected periodically using 1% permethrin-treated Þlter papers (Yoon et al. 2006) . Filter papers (35 mm diameter, Whatman No. 1) were immersed into 1% permethrin dissolved in acetone (wt: vol) for 10 s and air dried in a dark fume hood for 20 Ð30 min. Mixed developmental stages (Þrst-third instars and adults) were placed on the treated Þlter paper and exposed for 5 h. Surviving lice were transferred back onto the in vitro rearing system. The SF-HL strain has been determined previously to be susceptible to Ovide (0.5% malathion), resistant to Nix (1% permethrin) and cross-resistant to DDT treatments (Yoon et al. 2003) .
Chemicals. Both 0.5% and 1% precommercial ivermectin (MK-0933) topical cream formulations and the same formulation without ivermectin (placebo) were supplied through Topaz Pharmaceuticals LLC (Horsham, PA). In addition to ivermectin, formulated ivermectin contained deionized water, olive oil USP (United State Pharmacopeial), surfactants, shea butter, sorbitan tristearate, methylparaben, and propylparaben. Placebo contained all these components except ivermectin. Technical ivermectin (PS-2220, 4% B 1b and 94% B 1a , 98% pure) was obtained from Chem Services Inc., West Chester, PA). Dimethyl sulfoxide (DMSO) was obtained from Sigma (D-8779; St. Louis, MO).
Ovicidal Bioassays. Louse eggs, which were oviposited onto human hair tufts, were treated with and without ivermectin in various formulations and solvents to assess the ovicidal properties of ivermectin. Treatments included a 0.5% ivermectin topical cream formulation and the same formulation without ivermectin (placebo). Unformulated technical ivermectin was prepared at 0.5% in DMSO, diluted with distilled, deionized water (ddw) at 4:1 (vol:vol) and used to determine mortality of ivermectin in DMSO:ddw (unformulated) versus ivermectin in cream formulation (formulated). The DMSO:ddw treatment was used as a solvent control for unformulated ivermectin treatments. Eggs were laid on hair tufts (Ϸ300 strands, 5 cm in length) over a 48 h period and collected from feeding cups containing 30 male and 30 female lice. The day that adults were placed into feeding cups was designated day 0 and development stage was determined from this date. After 48 h, adults were removed and the hair tufts with eggs were divided into three equal groups: group 1 (0 Ð2 d old eggs), group 2 (3Ð5 d old eggs), and group 3 (6 Ð 8 d old eggs). Group 1 was treated on day 2, group 2 was treated on day 5, and group 3 was treated on day 8 postinfestation of the tufts by adults.
Tufts with 60 attached eggs were treated by gently swirling them into the treatment (Ϸ0.5 ml dispensed onto the surface of a glass petri dish) until they were completely covered and saturation was achieved. Treated tufts were placed in a glass dish for a 10 min exposure period at room temperature. At the end of the exposure period, each treated tuft with attached eggs was sequentially washed in three separate ddw baths (50 ml each) for 30 s per wash (hair tufts were swirled in a circular motion Ϸ20 cycles per wash) and dried on Þlter paper for 5 min at room temperature. Dried tufts with treated eggs were placed into covered sterile glass petri dishes and held in an incubator at 31ЊC, 70 Ð 80% RH.
The number of lice that hatched from eggs was recorded and used to determine the percent hatchability of eggs. Undeveloped eggs and stillborn lice were recorded as dead. Hatched lice were placed onto new hair tufts that had been treated and maintained exactly as the treated hair tufts with eggs and moved to a feeding cup maintained on the in vitro rearing system. Survivorship through larval development and adulthood was determined daily.
An additional experiment was performed to assess the possible mortality of hatched lice from residual ivermectin left on the treated hair tufts after washing. Eggs were treated with ivermectin formulation as described above, but then removed from the treated hair tuft immediately after drying by clipping the hair strand directly above and below the egg casing. These eggs were placed onto new untreated hair tufts and incubated at 31ЊC, 70 Ð 80% RH until hatch. Hatchability and survivorship were determined as described above.
All treatments were replicated three times with 60 eggs per replicate. SigniÞcant differences of means from treated eggs versus the means of appropriate controls were determined using StudentÕs t-test (P Ͻ 0.05).
Sub-Lethal Concentration of Ivermectin Formulation. The precommercial 1% ivermectin topical cream formulation (10 mg/ml) was diluted using placebo formulation (formulation without ivermectin) to 10, 2, 1, 0.2, 0.15, and 0.1 g/ml. Three groups of aged eggs (0 Ð2, 3Ð5, and 6 Ð 8 d postoviposition), which had been oviposited on human hair tufts, were treated with the diluted formulations given above. A hair tuft with a single group of aged eggs was gently swirled into a diluted formulation (Ϸ0.5 ml) that had been dispensed onto a glass petri dish until all hairs and attached eggs were completely covered with formulation by visual examination (Ϸ30 s of stirring). Placebo (cream formulation without ivermectin)-treated eggs were used as a negative treatment control for these experiments.
After a 10 min exposure, each tuft was sequentially washed three times as described above. Washed tufts were air dried on Þlter paper for 5 min at room temperature. Eggs were carefully removed from the treated hair tufts by clipping the hair directly above and below the egg, placed into a covered glass petri dish containing a gauze patch (Ϸ26 mm in diameter; Mirasorb, Johnson & Johnson, New Brunswick, NJ) and transferred to an incubator (31ЊC, 70 Ð 80% RH). All treatments were replicated three times using 60 eggs per treatment.
Newly hatched Þrst instars (50 lice/treatment or control) were relocated onto new untreated hair tufts, transferred to feeding units, and placed on the in vitro rearing system. Percent mortality was determined every 24 h over the bioassay period of 5 d (maximum time for Þrst instars to develop into second instars) posttreatment. A louse was considered dead if it could not right itself when inverted and when its legs ceased all movements when probed.
A Log-rank (Mantel-Cox) test was performed between treatments and controls to determine signiÞ-cant differences in louse mortality over the 5 d bioassay period (GraphPad Prism v.5.03, GraphPad Software, LA Jolla, CA). Statistical signiÞcance was established at the P Ͻ 0.05 level for all tests. Additionally, all lice were examined every 24 h over a period of 2 d to visually assess their ability to feed on the in vitro rearing system. Lice were considered fed by the presence of blood meal in their guts when visually examined under a dissecting microscope. StudentÕs t-test (P Ͻ 0.05) was performed between treatments and controls to determine signiÞcant differences in the percent of lice feeding. The feeding unit and hair tufts with lice were separately washed three times with ddw (0.5 ml/wash). The inside surfaces of the top part of the feeding unit, which housed the hair tufts with lice attached, were washed by dispensing ddw onto the top surface of the feeding membrane and gently swirling the unit for 30 s to solubilize any deposited louse excretions. Hair tufts with lice were washed by completely submerging them into 0.5 ml of ddw as described above. Washed hair tufts and lice were transferred separately to 0.5 ml microcentrifuge tubes and centrifuged at 5,000 ϫ g for 10 min to collect the remaining ddw from tufts and lice, respectively. Washes from each of the three extractions were combined into a liquid scintillation vial and dried completely under N 2 . The dried sample was resuspended into 0.5 ml of Soluene (Perkin Elmer, Waltham, MA) by incubation for 30 Ð 60 min at 55ЊC. To decolorize the dissolved sample, 100 l of 30% hydrogen peroxide solution (vol:vol in ddw) was added. Hionic-ßuor (5 ml, Perkin Elmer) was added and radioactivity in counts per min (cpm) determined using a liquid scintillation spectrophotometer (1209 Rackbeta, Wallac Inc., Gaithersburg, MD).
Washed lice were homogenized in Soluene (0.5 ml) using a glass-glass homogenizer (30 strokes/30 s, 7 ml, Kontes Glass Co., Vineland, NJ) and incubated for 30 min at 55ЊC. The homogenate was transferred to a liquid scintillation vial and decolorized as described above. The homogenizer was washed an additional two times with 0.5 ml Soluene and the washes were combined with the original homogenate. Hionic-ßuor (5 ml) was added and radioactivity (cpm) determined spectrophotometrically as described above.
A 10 l aliquot of human blood from the blood reservoir of the feeding unit was transferred to a liquid scintillation vial containing Soluene (0.5 ml) and incubated for 30 Ð 60 min at 55ЊC. The sample was decolorized and radioactivity (cpm) determined spectrophotometrically as described above. These data were statistically analyzed using StudentÕs t-test (P Ͻ 0.05) to determine signiÞcant increases in the ingestion and excretion of [ ] inulin were constructed as described above and used to determine the feeding activity of Þrst instars that hatched from 6 to 8 d old eggs treated with sub-lethal (0.1 g/ml) and semilethal (0.15 and 0.2 g/ml) concentrations of diluted 1% ivermectin topical cream formulation over a 48 h feeding interval after eclosion. Three replicates of Þrst instars hatched from 6 to 8 d old treated eggs (50 lice/replicate) were transferred to feeding units containing [ and determination of the amount of [ 3 H] inulin ingested. Extraction procedures were performed and the number of cpm in each extract was determined spectrophotometrically as described above.
These data were statistically analyzed using StudentÕs t-test (P Ͻ 0.05) to determine signiÞcant difference in the feeding activity of lice that hatched from eggs treated with diluted ivermectin formulations versus lice that hatched from eggs treated with placebo.
Results

Hatchability, Feeding, and Survivorship of Lice
Hatched From Ivermectin-Treated Eggs. Treatment of eggs with either 0.5% ivermectin topical cream formulation or 0.5% ivermectin in DMSO:ddw resulted in no signiÞcant differences in the percentage of eggs that hatched compared with treatment with either placebo or DMSO:ddw, respectively, for any of the three aged groups of eggs (Table 1) . The percentages of hatched lice that took a blood meal from eggs treated with either 0.5% ivermectin formulation or 0.5% ivermectin in DMSO:ddw, however, were significantly decreased (82Ð95% and 88 Ð92% fewer fed, respectively) compared with the percentage that fed when hatched from eggs treated with either placebo or DMSO:ddw, respectively, for all three aged egg groups. All hatched lice from eggs treated with either 0.5% ivermectin formulation or 0.5% ivermectin in DMSO:ddw died as Þrst instars within 48 h, including those hatched lice that fed.
There were no signiÞcant differences between any of the results obtained after treatment with either 0.5% ivermectin formulation or 0.5% ivermectin in DMSO: ddw for any of the three aged egg groups (Table 1) . Likewise, there were no signiÞcant differences in the responses obtained from eggs treated with ddw, DM-SO:ddw, or placebo for any of the three aged egg groups.
Determination of Sub-Lethal Concentrations of Formulated and Unformulated Ivermectin Used to Assess Feeding in the Absence of Ivermectin Mortality. Because there were no signiÞcant differences in the percentages of hatch, fed, or survivorship between the 0.5% ivermectin topical cream formulation versus the unformulated ivermectin (0.5% ivermectin in DMSO:ddw) treatments, both within an egg developmental stage and between egg developmental stages (Table 1) , 6 Ð 8 d old eggs were used to determine sub-lethal concentrations of diluted ivermectin formulation to assess feeding in the absence of ivermectin mortality.
The day 1 (24 h posteclosion) mortality responses to the 10, 2, and 1 g/ml ivermectin formulation dilutions were signiÞcantly greater than the responses to placebo (Log-rank test, 2 ϭ 446.4, df ϭ 6, P Ͻ 0.0001) ( Table 2 ). The mortality responses to the 0.1, 0.15, and 0.2 g/ml ivermectin formulation dilutions, however, were not signiÞcantly different from the responses to the placebo (Log-rank test, 2 ϭ 1.9, df ϭ 3, P Ͼ 0.05) ( Table 2 ). Of the treatments that did not result in signiÞcant mortality, the 0.15 and 0.2 g/ml dilutions signiÞcantly reduced the percentage of lice that fed on day 1 (9 and 16% less lice fed when hatched from eggs treated with diluted ivermectin formulations compared with lice that hatched from eggs treated with placebo 24 h after hatch) (StudentÕs unpaired t-test, t ϭ 55.25, df ϭ 298, P Ͻ 0.0001).
Feeding Ability of Lice Hatched From Untreated Eggs. The amount of [ 3 H] inulin detected in blood from the feeding reservoir did not signiÞcantly change over the 1, 24, and 48 h feeding intervals used to expose Þrst instars to [ 3 H] inulin-infused blood (Fig. 1A) . The amount of [ 3 H] inulin detected in the extracts of whole body homogenates after ingestion by blood feeding (ingested but not yet excreted, internal cpm), however, did signiÞcantly increase over the 1Ð24 h feeding interval (t ϭ 3.5, df ϭ 4, P ϭ 0.03) but did not further increase between the 24 Ð 48 h feeding intervals (Fig. 1B) .
The amount of [ 3 H] inulin detected in the rinse/ excrement extracts (excreted cpm) signiÞcantly increased over the 1Ð24 h feeding intervals (t ϭ 6.0, df ϭ 4, P ϭ 0.004) and between the 24 Ð 48 h feeding intervals (t ϭ 3.4, df ϭ 4, P ϭ 0.03) (Fig. 1C) .
The total amount of [ creased over the 1Ð24 h (4.2-fold) (t ϭ 5.1, df ϭ 4, P ϭ 0.007) and 1Ð 48 h (8.4-fold) (t ϭ 7.4, df ϭ 4, P ϭ 0.002) feeding intervals and between the 24 Ð 48 h feeding intervals (two-fold) (t ϭ 0.02, df ϭ 4, P ϭ 0.02) (Fig. 2) .
Feeding Ability of Lice Hatched From IvermectinTreated Eggs. The amounts of [
3 H] inulin ingested over the 1, 24, and 48 h feeding intervals were likewise determined for Þrst instars that hatched from 6 to 8 d old eggs treated with a sub-lethal (0.1 g/ml) and semilethal (0.15 and 0.2 g/ml)dilutions of ivermectin topical cream formulation. The amount of [ 3 H] inulin detected in blood from feeding reservoirs did not signiÞcantly change over time for any of the treatments (placebo: t ϭ 1.7, P ϭ 0.2; 0.1 g/ml: t ϭ 0.8, P ϭ 0.4; 0.15 g/ml: t ϭ 0.8, P ϭ 0.5; 0.2 g/ml; t ϭ 0.5, P ϭ 0.6; all df ϭ 4) (Fig. 3A) .
Within treatments, the amounts of [ 3 H] inulin detected in whole body homogenates signiÞcantly increased from the one to the 24 h feeding intervals for the placebo (t ϭ 3.5, df ϭ 4, P ϭ 0.03) and the 0.1 (t ϭ 3.5, df ϭ 4, P ϭ 0.03) and 0.2 (t ϭ 1.9, df ϭ 4, P ϭ 0.01) g/ml diluted ivermectin formulation treatments (Fig. 3B) . Although not statistically signiÞcant, the amount of [ 3 H] inulin detected in whole body homogenates also increased from the one to the 24 h feeding intervals for the 0.15 g/ml diluted ivermectin formulation treatment (t ϭ 1.9, df ϭ 4, P ϭ 0.14). There were no further statistically signiÞcant increases in the amounts of [ 3 H] inulin detected in whole body homogenates from the 24 to the 48 h feeding interval for any of the treatments (placebo: t ϭ 0.9, P ϭ 0.4; 0.1 g/ml: t ϭ 1.8, P ϭ 0.15; 0.15 g/ml: t ϭ 0.05, P ϭ 1.0; 0.2 g/ml: t ϭ 1.7, P ϭ 0.2; all df ϭ 4). Although not signiÞcant, there was a consistent dose-dependent decrease in the amount of [ H] inulin excreted) signiÞcantly increased from the one to the 24 h feeding intervals for Þrst instars that emerged from placebo-treated eggs (t ϭ 6, df ϭ 4, P ϭ 0.004) and for Þrst instars that emerged from eggs treated with diluted ivermectin formulation treatments (0.1 g/ml: t ϭ 2.4, df ϭ 4, P ϭ 0.08; 0.15 g/ml: t ϭ 7.8, df ϭ 4, P ϭ 0.001; and 0.2 g/ml: t ϭ 4.9, df ϭ 4, P ϭ 0.008 (Fig. 3C) . The amounts of [ 3 H] inulin detected in the rinse/excrement extracts also signiÞcantly increased from the 24 to the 48 h feeding intervals for Þrst instars from placebo-treated eggs (t ϭ 5, df ϭ 4, P ϭ 0.008) and for Þrst instars from eggs treated with diluted ivermectin formulations (0.1, 0.15, 0.2 g/ml treatments; t ϭ 4.4, df ϭ 4, P ϭ 0.01; t ϭ 4.3, df ϭ 4, P ϭ 0.01; t ϭ 4.7, df ϭ 4, P ϭ 0.009) (Fig. 3C) .
The amounts of [ 3 H] inulin detected in the rinse/ excrement extracts at the 24 and 48 h feeding intervals, however, signiÞcantly decreased from Þrst instars that emerged from eggs treated with the 0.2 g/ml ivermectin formulation treatment compared with Þrst instars that emerged from eggs that received only placebo (t ϭ 4.7, df ϭ 4, P ϭ 0.009 and t ϭ 5, df ϭ 4, P ϭ 0.008, respectively) (Fig. 3C) . Although only signiÞ-cantly less in the presence of the 0.2 g/ml treatment, there was a consistent dose-dependent decrease in the amount of [ 3 H] inulin excreted at 48 h with increasing concentrations of diluted ivermectin formulation (Ϫ12.7% at 0.1, Ϫ37.4% at 0.15, and Ϫ60.3% at 0.2 g/ml) compared with the placebo treatment (t ϭ 1.0, P ϭ 4; t ϭ 2.5, P ϭ 0.07; t ϭ 4.7, P ϭ 0.009, respectively, all df ϭ 4). The total amount of [ 3 H] inulin ingested was determined by combining the cpm from the whole body homogenate and rinse/excrement extracts (Fig. 4) . Within treatments, the total amount of [ 3 H] inulin ingested signiÞcantly increased from the one to the 24 h feeding intervals for the placebo (t ϭ 5.1, df ϭ 4, P ϭ 0.007) and for the 0.1, 0.15, and 0.2 g/ml diluted ivermectin formulation treatments (t ϭ 4.3, P ϭ 0.01; t ϭ 5.2, P ϭ 0.006; t ϭ 4.8, P ϭ 0.01, respectively, all df ϭ 4). At the 48 h feeding interval, only the placebo treatment signiÞcantly increased the total amount of [ 3 H] inulin ingested compared with the placebo treatment value at 24 h (t ϭ 3.6, df ϭ 4, P ϭ 0.02).
The amounts of [ 3 H] inulin ingested were not signiÞcantly decreased by any of the diluted ivermectin formulation treatments at 24 h compared with the placebo treatment at 24 h. There was a concentrationdependent decrease, nevertheless, in the presence of 0.15 and 0.2 g/ml diluted ivermectin formulation treatments compared with placebo treatment. The amount of [ 3 H] inulin ingested did signiÞcantly decrease, however, in the presence of the 0.15 and 0.2 g/ml ivermectin treatments compared with placebo at 48 h (t ϭ 2.9, df ϭ 4, P ϭ 0.04 and t ϭ 4.5, df ϭ 4, P ϭ 0.01, respectively). Although only signiÞcantly less at the 0.15 and 0.2 g/ml treatment levels, there was a consistent dose-dependent decrease in the amount of [ 3 H] inulin ingested at the 48 h exposure interval with increasing concentrations of diluted ivermectin formulation (Ϫ16.1% at 0.1, Ϫ36.3% at 0.15, and Ϫ54.8% at 0.2 g/ml).
Discussion
Ivermectin was not directly ovicidal as hatchability was not different from controls. Nevertheless, all lice that hatched died without the need of a second treatment. There was also a 10-to 20-fold decrease in the percentage of hatched lice that took a blood meal after egg treatment, suggesting that ivermectin may be affecting the proper function of the blood sucking mouthparts necessary for feeding. Ivermectin-treated eggs that hatched on new untreated tufts still died within 48 h, suggesting that if there was any residual ivermectin left on the hair tuft after rinsing, it would have been in trace amounts insufÞcient to inßuence the viability of the hatched instars. Mortality of these Þrst instars may then be because of ivermectin either penetrating the egg casing during egg treatments or because of ivermectin on the outside of the egg that hatched lice contacted during emergence. Regardless, Þrst instars that hatch from eggs treated with iver- mectin apparently received a sufÞcient amount to stop them from successfully feeding.
This observation led us to hypothesize that ivermectin may be acting on the glutamate-gated chloride channels associated with the neuromuscular system controlling the louse piecing-sucking mouthparts in much the same way it acts on the pharyngeal pump of nematodes (Portillo et al. 2003, Wolstenholme and Rogers 2010) . To show that ivermectin could decrease blood feeding in the absence of mortality, eggs were treated with 0.15 and 0.2 g/ml of diluted ivermectin formulation. These treatments resulted in no signiÞ-cant increase in mortality but signiÞcantly decreased the percentage of Þrst instar lice that took a blood meal at 24 h posteclosion. This process appears to be because of decreased feeding over time as indicated by the signiÞcant decrease in [ 3 H] inulin ingestion at this same time posteclosion and at the same ivermectin concentrations used to treat eggs. Thus, it appears that ivermectin is not directly ovicidal but is acting as a potent posteclosion nymphicide that prevents the Þrst instar louse from feeding successfully. This action is apparently due solely to ivermectin as similar results were obtained with both the formulated and unformulated ivermectin treatments.
One possibility is that ivermectin is acting at the glutamate-gated chloride channels in the louseÕs neuromuscular system that controls its sucking mouthparts during blood feeding. It is well established that ivermectin: (1) decreased feeding in nematodes (McCavera et al. 2007 ), (2) decreased larval feeding and growth occur at 10-to 100-fold lower concentrations than those necessary to initiate larval mortality (Browlee et al. 1997) , and (3) affects the feeding of ivermectin-resistant nematodes less than susceptible nematodes (Paiement et al. 1999 , Alvarez-Sanchez et al. 2005 . Ivermectin decreases feeding by inhibiting the pharyngeal pump by binding to inhibitory gluta- mate-gated chloride channels. This causes hyperpolarization and paralysis of the neuromuscular mouthparts (Cully et al. 1994 , Paiement et al. 1999 .
Although little information is available that directly implicates that a similar system is operational in insects with sucking mouthparts, there is some. Using the ivermectin-resistance strain of Drosophila melanogasterglc 1 (glc 1 ) Kane et al. (2000) showed that binding of ivermectin to the glc 1 head membrane preparation was markedly reduced compared with the same preparation from the susceptible strain and that the glc 1 strain possessed a novel mutation (P299S) in the gene that encodes the glutamate-gated chloride channel subunit DmGluCl␣. Mutant and wild-type channels were heterologously expressed in Xenopus laevis oocytes and the mutant channel found to be Ϸ10-fold less sensitive to ivermectin activation, providing direct evidence that ivermectin acts on DmGluCl␣ channels. Similarly, a point mutation (G323D) in the glutamategated chloride channel TuGluCl from an abamectinresistant strain of two-spotted spider mite was also identiÞed and found to confer abamectin resistance (Kwon et al. 2010) . Lastly, both the human body and head louse genomes possess a putative glutamategated chloride channel, which is orthologous to DmGluCl␣ and TuGluCl (Kirkness et al. 2010) . Nevertheless, our hypothesis that ivermectin is acting on the louse glutamate-gated chloride channel in a similar manner as seen in nematodes is only speculation at this time and only one of many possibilities. Thus, glutamate-gated chloride channels from human lice need to be cloned and functionally expressed in Xenopus laevis oocytes to determine the direct the action of ivermectin on these channels. Once identiÞed, immunohistochemistry is necessary to determine the channels expression pattern.
If this hypothesis is proven true, there are signiÞcant ramiÞcations of this Þnding. First, glutamate-chloride channels are unique to invertebrates, including insects, and are not found in humans. Thus, this receptor may constitute a selective target site for the development of new insecticides, such as glutamate-gated chloride channel-directed avermectins that are toxic to insects but not to humans. Second, the potency of ivermectin at glutamate-gated chloride channels controlling feeding appears to be quite high. Therefore, extremely low doses of ivermectin should be effective in killing nymphs as they emerge from their eggs and attempt to feed. This low dose is expected to have no effect on humans because percutaneous absorption of ivermectin is poor, and because only the less sensitive GABA-gated chloride channels are present in humans.
